Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05991908 | Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies | recruiting | Phase 3 | 222 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06802718 | Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | recruiting | Phase 3 | 96 | Peking University People's HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06740916 | Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance | recruiting | Phase 3 | 240 | Siriraj HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT04168502 | Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | recruiting | Phase 3 | 414 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04655092 | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | recruiting | Phase 3 | 67 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06418776 | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | recruiting | Phase 3 | 198 | National Research Center for Hematology, RussiaNETWORK | 1 | May 17, 2024 | clinicaltrials |
| NCT06345365 | MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 154 | Zhongnan HospitalOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML(VHA) | recruiting | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | recruiting | Phase 2 / Phase 3 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Feb 18, 2025source: clinicaltrials